ATE459350T1 - Behandlung von schwerer aphasie bei chronischen zerebrovaskulären erkrankungen - Google Patents
Behandlung von schwerer aphasie bei chronischen zerebrovaskulären erkrankungenInfo
- Publication number
- ATE459350T1 ATE459350T1 AT04807730T AT04807730T ATE459350T1 AT E459350 T1 ATE459350 T1 AT E459350T1 AT 04807730 T AT04807730 T AT 04807730T AT 04807730 T AT04807730 T AT 04807730T AT E459350 T1 ATE459350 T1 AT E459350T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- cerebrovascular diseases
- chronic cerebrovascular
- severe aphasia
- aphasia
- Prior art date
Links
- 201000007201 aphasia Diseases 0.000 title abstract 2
- 208000026106 cerebrovascular disease Diseases 0.000 title abstract 2
- 230000001684 chronic effect Effects 0.000 title abstract 2
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003427424 | 2003-12-24 | ||
| PCT/JP2004/019373 WO2005061454A1 (ja) | 2003-12-24 | 2004-12-24 | 脳血管障害慢性期の重度失語症に対する治療剤又は治療方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE459350T1 true ATE459350T1 (de) | 2010-03-15 |
Family
ID=34708892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04807730T ATE459350T1 (de) | 2003-12-24 | 2004-12-24 | Behandlung von schwerer aphasie bei chronischen zerebrovaskulären erkrankungen |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1698622B1 (de) |
| JP (1) | JPWO2005061454A1 (de) |
| AT (1) | ATE459350T1 (de) |
| DE (1) | DE602004025849D1 (de) |
| ES (1) | ES2340040T3 (de) |
| WO (1) | WO2005061454A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2380111C2 (ru) * | 2007-07-13 | 2010-01-27 | Государственное учреждение "Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева" (НИПИ им. В.М. Бехтерева) | Способ лечения афазий |
| LV14346B (lv) * | 2009-11-05 | 2011-07-20 | Grindeks, A/S | 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2440634A1 (de) * | 1974-08-24 | 1976-03-04 | Chemisches Lab Fritzwalter Lan | Verfahren zur herstellung von (2-oxopyrrolidin-1)-acetamid |
| RU2145895C1 (ru) * | 1996-12-24 | 2000-02-27 | Главный военный клинический госпиталь им.акад.Н.Н.Бурденко | Способ лечения церебрального ишемического инсульта |
-
2004
- 2004-12-24 ES ES04807730T patent/ES2340040T3/es not_active Expired - Lifetime
- 2004-12-24 JP JP2005516525A patent/JPWO2005061454A1/ja active Pending
- 2004-12-24 EP EP04807730A patent/EP1698622B1/de not_active Expired - Lifetime
- 2004-12-24 AT AT04807730T patent/ATE459350T1/de not_active IP Right Cessation
- 2004-12-24 DE DE602004025849T patent/DE602004025849D1/de not_active Expired - Lifetime
- 2004-12-24 WO PCT/JP2004/019373 patent/WO2005061454A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1698622A4 (de) | 2007-08-08 |
| EP1698622A1 (de) | 2006-09-06 |
| WO2005061454A1 (ja) | 2005-07-07 |
| DE602004025849D1 (de) | 2010-04-15 |
| JPWO2005061454A1 (ja) | 2007-07-12 |
| ES2340040T3 (es) | 2010-05-28 |
| EP1698622B1 (de) | 2010-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0413234A (pt) | derivados de imidazola bicìclica contra flaviviridae | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| ATE544748T1 (de) | Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen | |
| BR0307058A (pt) | N-óxidos de derivados de n-fenil-2-pirimidina-amina | |
| EP1551812A4 (de) | Mitotische kinesinhemmer | |
| DE602004024572D1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| DE60314500D1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
| EP1481077A4 (de) | Mitotische kinesin-hemmer | |
| ATE356804T1 (de) | Inhibitoren von mitotischem kinesin | |
| ATE480255T1 (de) | Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen | |
| DE60222302D1 (de) | Inhibitoren von mitotischem kinesin | |
| EP1626730A4 (de) | Verfahren, gerät und zusammensetzung zur behandlung von akne | |
| ATE458485T1 (de) | Ubiquitin-ligase-hemmer und verwandte verfahren | |
| ATE448775T1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
| DE60103171D1 (de) | Verfahren und verbindungen zur behandlung proliferativer erkrankungen | |
| DE602004012578D1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
| ATE497763T1 (de) | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen | |
| ATE462702T1 (de) | Für die behandlung von entzündlichen krankheiten nützliche beta-carboline | |
| ATE423110T1 (de) | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen | |
| DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
| ATE359816T1 (de) | Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren | |
| ATE495735T1 (de) | Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden | |
| ATE459350T1 (de) | Behandlung von schwerer aphasie bei chronischen zerebrovaskulären erkrankungen | |
| ATE426605T1 (de) | Inhibitoren von mitotischem kinesin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |